10x Genomics is trading 5.16% up now at $47.89 after its August 6 earnings beat revenue expectations and management raised full-year 2026 revenue guidance.
- Guidance is $610 million-$630 million, supported by strong initial demand for the Atera spatial platform.
- Gross margin expanded to 74%.
- Investors are weighing the upbeat full-year view against an expected modest third-quarter sequential decline before a stronger fourth-quarter Atera ramp.